Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination.

Autor:	Stone VM; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden., Utorova R; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden., Butrym M; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden., Sioofy-Khojine AB; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland., Hankaniemi MM; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland., Ringqvist EE; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden., Blanter M; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden., Parajuli A; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden., Pincikova T; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.; Stockholm CF Center, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.; Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden., Fischler B; Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden., Karpati F; Stockholm CF Center, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.; Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden., Hytönen VP; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.; Fimlab Laboratories, 33520 Tampere, Finland., Hyöty H; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.; Fimlab Laboratories, 33520 Tampere, Finland., Hjelte L; Stockholm CF Center, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.; Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden., Flodström-Tullberg M; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2022 Sep 05; Vol. 25 (10), pp. 105070. Date of Electronic Publication: 2022 Sep 05 (Print Publication: 2022).
DOI:	10.1016/j.isci.2022.105070
Abstrakt:	Viral respiratory tract infections exacerbate airway disease and facilitate life-threatening bacterial colonization in cystic fibrosis (CF). Annual influenza vaccination is recommended and vaccines against other common respiratory viruses may further reduce pulmonary morbidity risk. Enteroviruses have been found in nasopharyngeal samples from CF patients experiencing pulmonary exacerbations. Using serology tests, we found that infections by a group of enteroviruses, Coxsackievirus Bs (CVBs), are prevalent in CF. We next showed that a CVB vaccine, currently undergoing clinical development, prevents infection and CVB-instigated lung damage in a murine model of CF. Finally, we demonstrate that individuals with CF have normal vaccine responses to a similar, commonly used enterovirus vaccine (inactivated poliovirus vaccine). Our study demonstrates that CVB infections are common in CF and provides experimental evidence indicating that CVB vaccines could be efficacious in the CF population. The role of CVB infections in contributing to pulmonary exacerbations in CF should be further studied. Competing Interests: H.H. owns stocks in, and is the chairman of, the board of Vactech Ltd that develops vaccines against picornaviruses. H.H. and M.F.T. serve on the scientific advisory board of Provention Bio Inc. that develops vaccines against Coxsackie B viruses in collaboration with Vactech Ltd. The remaining authors declare that they have no conflict of interests. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu